Form 4: Stoke Therapeutics Officer Converts RSUs

Stoke Therapeutics' Chief Patient Officer, Jason Hoitt, converted 10,000 restricted stock units into common stock on March 15, 2026.

Summary

• Jason Hoitt, Chief Patient Officer of Stoke Therapeutics, Inc. (STOK), reported a transaction on March 15, 2026.
• Hoitt acquired 10,000 shares of common stock through the exercise/conversion of derivative securities.
• The acquisition price for these shares was $0.
• Following this transaction, Hoitt beneficially owns 13,988 shares of common stock, which includes an aggregate of 2,186 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan.
• Hoitt disposed of 10,000 Restricted Stock Units (RSUs) as part of this conversion.
• He now beneficially owns 30,000 Restricted Stock Units.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
• The RSU award vests as to 1/4 of the total annually, beginning on March 15, 2026, subject to continued service to the Issuer through each vesting date.
• The expiration date for the RSUs is March 15, 2029.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it reflects a routine vesting of equity compensation for a key officer, indicating continued service and a vested interest in the company's performance.

Positives

• The conversion of RSUs into common stock indicates a vesting event, reflecting continued service and a vested interest in the company by a key officer.
• The officer's beneficial ownership of common stock increased by 10,000 shares from this transaction, plus additional shares from the Employee Stock Purchase Plan.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, such as RSU conversions, are common events in the biotechnology sector, reflecting executive compensation structures and vesting schedules. While this specific filing reports a routine equity compensation event, it provides insight into the Chief Patient Officer's vested equity stake in Stoke Therapeutics.

Stakeholder Impact

• Shareholders: Provides transparency regarding executive equity ownership and compensation structure.
• Employees: Reflects standard equity compensation practices within the company.

Next Steps

• Future annual vesting of the remaining 30,000 Restricted Stock Units on March 15th of subsequent years until fully vested by March 15, 2029, subject to continued service.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction involving the vesting and conversion of Restricted Stock Units (RSUs) by a Chief Patient Officer. Such events are standard components of executive compensation and do not typically signal a change in the company's fundamental outlook or operational performance. While it confirms the officer's continued vested interest, it lacks new information that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive operational or financial updates.

Keywords

Stoke Therapeutics, STOK, Form 4, Insider Transaction, Restricted Stock Units, RSU Conversion, Jason Hoitt, Chief Patient Officer, Equity Compensation